Explore the Agenda
7:30 am Check In, Morning Coffee & Light Refreshments
8:20 am Chair’s Opening Remarks
From Global Pharma Powerhouses to Regulatory Harmony – Showcasing the Outlook of Next Generation ADCs & Emerging Areas
8:30 am Precision Delivery of Therapeutics with Antibodies Through Biology, Chemistry & AI
- How antibodies enable more precise delivery of therapeutic payloads for oncology and beyond to selected tissues and cell types
- The biological and chemical challenges that determine whether targeted delivery translates into meaningful therapeutic benefit
- How AI is accelerating the design and optimization of next-generation antibody-enabled delivery systems
9:00 am Evaluating Phase & Product Appropriate Bioconjugate Development
- Exploring the differing development approaches of ADCs across the preclinical to commercial spectrum
- Understanding how the bioconjugate landscape now encompasses a wide variety of modalities with differing mechanisms of action and molecular structures
- Exploring relevant examples of how the requirements for process and analytical development can vary between different conjugates
9:30 am Fireside Discussion: A Regulatory Perspective on the Complexity of Global Policy & Market Dynamics Towards the Next ADC Approval Beyond TOPO-1
- What are the current regulatory guidelines and regional differences for ADC clinical and commercial pathways?
- How as a community can we work with the regulators to reduce impact on development timelines and bring ADCs as standard-of-care therapies?
- How are the regulators navigating complex ADC formats from dual-payload, bispecific and novel conjugation strategies?
10:00 am Morning Break & Networking
Discovery
Preclinical & Translational
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
Discovery
Discovery Track
Exploring Novel Antibody Engineering to Enhance ADC Performance
4 Sessions
Preclinical & Translational
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
12:00 pm Lunch Break & Networking
Discovery
Preclinical & Translational
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
Discovery
Translating ADC Discovery From In Vitro to In Vivo to Assess Potency & Therapeutic Efficacy of Novel Payloads
3 Sessions
Discovery & Development of Click-To-Release ADCs With Enhanced Therapeutic Potential
Co-Founder & Chief Scientific Officer, Tagworks Pharmaceuticals
- Using the learnings from our first-in-class clinical-stage click-cleavable ADC, TGW101, targeting TAG72, to inform next-generation designs and further expand the ADC target universe into the non-internalising target space
- Highlighting how the Click-to-Release linker system delivers a highly differentiated safety and efficacy profile across multiple payload classes
- Discussing protein design considerations and the functional characterisation of our discovery-phase ADCs
Preclinical & Translational
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain
2:30 pm Afternoon Break & Networking
Showcasing Innovative XDC Design Excellence to Improve Efficacy & Tolerability to Widen the Therapeutic Index
3:30 pm A Scalable Lysine Bioconjugation Platform: Reducing Development Burden as Clinical Demand Scales
- Presenting quality-based driven development
- Showcasing platform establishment
- Leveraging multiple programme efficiency
4:00 pm Engineering the Next-Generation Antibody-Oligonucleotide Drug Conjugates & Opportunities for New Disease Indications
- Moving beyond traditional payloads to oligonucleotide conjugates to deliver siRNA-based medicines to patients faster
- Leveraging the dual capability to open doors to interventions with reduced off-target effects, providing a pathway for highly precise treatments
- Utilising AOCs for targeted gene silencing: Overcoming the challenge of escaping from cellular compartments and achieving substantial target gene knockdown in solid tumours